---
title: "Foghorn Advances FHD-909 Trial and Strengthens Financial Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278801213.md"
description: "Foghorn Advances FHD-909 Trial and Strengthens Financial Position"
datetime: "2026-03-12T01:29:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278801213.md)
  - [en](https://longbridge.com/en/news/278801213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278801213.md)
generator: "portal-rs"
---

# Foghorn Advances FHD-909 Trial and Strengthens Financial Position

Foghorn Advances FHD-909 Trial and Strengthens Financial Position

### Related Stocks

- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)

## Related News & Research

- [Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright](https://longbridge.com/en/news/285715134.md)
- [Foghorn Therapeutics Q2 FY26 net loss narrows to $7.2 million; collaboration revenue rises to $16.1 million](https://longbridge.com/en/news/295098647.md)
- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)](https://longbridge.com/en/news/296112335.md)
- [Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR](https://longbridge.com/en/news/295771398.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**